ceperognastat   Click here for help

GtoPdb Ligand ID: 11953

Synonyms: LY-3372689 | LY3372689
PDB Ligand
Compound class: Synthetic organic
Comment: LY3372689 is a O-GlcNAcase (OGA) inhibitor that was developed by Eli Lilly as a Tau modulator for Alzheimer's disease. Its structure was revealed during the 'first disclosure' session at the ACS Spring 2022 meeting, and it is a chemical structure that is claimed in Eli Lilly's patent WO2018140299A1 [1]. Information from clinical trial records indicates that LY3372689 is administered orally. The structure for LY3372689 matches that for the INN ceperognastat (proposed list 132, Feb. 2025).
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species

ceperognastat is commercially available from our sponsors

2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 6
Hydrogen bond donors 1
Rotatable bonds 7
Topological polar surface area 121.62
Molecular weight 383.14
XLogP 0.66
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES CC(=O)Nc1nc(c(s1)CN1CC[C@@H](C[C@@H]1C)OCc1noc(n1)C)F
Isomeric SMILES C[C@H]1C[C@H](CCN1Cc1c(F)nc(NC(=O)C)s1)OCc1noc(C)n1
InChI InChI=1S/C16H22FN5O3S/c1-9-6-12(24-8-14-19-11(3)25-21-14)4-5-22(9)7-13-15(17)20-16(26-13)18-10(2)23/h9,12H,4-8H2,1-3H3,(H,18,20,23)/t9-,12-/m0/s1
InChI Key FRVXHWNHGWUTQO-CABZTGNLSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
No information available.
Summary of Clinical Use Click here for help
LY3372689 has been advanced to Phase 2 clinical evaluation to determine efficacy in aptients with Alzheimer's Disease.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03819270 A Safety Study of LY3372689 Given By Mouth to Healthy Participants Phase 1 Interventional Eli Lilly and Company
NCT05063539 A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease Phase 2 Interventional Eli Lilly and Company